Follow-up blood cultures in *Pseudomonas aeruginosa* bacteremia: A potential target for diagnostic stewardship

Alexis L. Green BA1, Yuanyuan Liang PhD, MSc2, Lyndsay M. O’Hara PhD, MPH2, Lisa Pineles MA2, Scott Sorongon BS2, Anthony D. Harris MD, MPH2 and Jonathan D. Baghdadi MD, PhD2

1University of Maryland School of Medicine, Baltimore, Maryland and 2Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland

Abstract

Objectives: Evidence supporting collection of follow-up blood cultures for Gram-negative bacteremia is mixed. We sought to understand why providers order follow-up blood cultures when managing *P. aeruginosa* bacteremia and whether follow-up blood cultures in this context are associated with short- and long-term survival.

Methods: We conducted a retrospective cohort study of adult inpatients with *P. aeruginosa* bacteremia at the University of Maryland Medical Center in 2015–2020. Kaplan-Meier survival curves and Cox regression with time-varying covariates were used to evaluate the association between follow-up blood cultures and time to mortality within 30 days of first positive blood culture. Provider justifications for follow-up blood cultures were identified through chart review.

Results: Of 159 eligible patients, 127 (80%) had follow-up blood cultures, including 9 (7%) that were positive for *P. aeruginosa* and 10 (8%) that were positive for other organisms. Follow-up blood cultures were typically collected “to ensure clearance” or “to guide antibiotic therapy.” Overall, 30-day mortality was 25.2%. After risk adjustment for patient characteristics, follow-up blood cultures were associated with a non-significant reduction in mortality risk (hazard ratio, 0.43; 95% confidence interval, 1.08; *P* = .071). In exploratory analyses, the potential mortality reduction from follow-up blood cultures was driven by their use in patients with Pitt bacteremia scores >0.

Conclusions: Follow-up blood cultures are commonly collected for *P. aeruginosa* bacteremia but infrequently identify persistent bacteremia. Targeted use of follow-up blood cultures based on severity of illness may reduce unnecessary culturing.

Keywords: *Pseudomonas aeruginosa*; follow-up blood cultures; diagnostic stewardship

(Received 26 April 2021; accepted 15 July 2021)
were excluded. For patients who had >1 hospital stay in which they had a positive *P. aeruginosa* blood culture, only the first hospital stay was included. This study was deemed exempt from review by the University of Maryland Baltimore Institutional Review Board.

**Data collection**

Data were extracted from the electronic medical records of each patient and supplemented with chart review. All data elements extracted electronically were validated by chart review in a random sample of 20 charts. The variables we investigated included demographic information (age, sex, race, and BMI), clinical characteristics (source of bacteremia, presence of a Foley catheter or central line at the time of the first positive blood culture), and components of the Pitt bacteremia score (temperature, blood pressure, cardiac arrest, mechanical ventilation, and mental status).9,10 The primary outcome was time in days from the first positive blood culture to all-cause mortality for up to 30 days of follow-up. A 30-day follow-up period was chosen to capture clinical outcomes during the acute phase of illness which might occur after hospital discharge. Mortality events were identified through review of connected electronic health records available on the Care Everywhere Network provided by Epic and review of records from CRISP, the designated health information exchange for the state of Maryland.11 Individuals who did not have documented follow-up at least 30 days after the index positive blood culture were censored at the time of last documented living interaction with healthcare. Individuals who had documented living interaction 30 days after the index positive blood culture were censored at 30 days. A sensitivity analysis was performed using time from the first positive blood culture to mortality within a 90-day follow-up period as the outcome.

Source of bacteremia was determined by review of progress notes from the infectious disease consultant or primary team. Charts were independently reviewed by 2 members of the study team (A.G. and J.B.) in sets of 10, with a third team member available for adjudication (A.H.). Once agreement between the 2 reviewers reached >90%, remaining charts were reviewed by a single individual (A.G.). Documented justification for follow-up blood culture was collected from the progress note of the infectious disease consultant or primary team.

**Definitions**

Blood cultures were categorized as follow-up if collected >24 hours and ≤7 days after the index positive, in accordance with the literature.3 In time-to-event analysis, the exposure of interest was a time-varying binary variable representing the presence of follow-up blood culture at a given time after the index positive blood culture (time 0). Physician justification for follow-up blood culture was defined by documentation of a reason for follow-up blood cultures on the day before, day of, or day after collection. Baseline health was represented using the sum of conditions present from the Elixhauser comorbidity index as defined using *International Classification of Disease, Tenth Revision* (ICD-10) codes.12 Hospital-onset bacteremia was defined by the index positive blood culture occurring after hospital day 3. The Pitt bacteremia score was calculated using the most abnormal values for each contributing element from the calendar day of the index positive blood culture. In multivariable analyses, Pitt bacteremia scores were categorized as low (a score of 0), moderate (scores 1–4), and high (scores ≥5) based on thresholds from the literature used to indicate severe infection.13 Antimicrobial resistance, selection of antibiotic coverage, and use of empiric therapy were captured in a single variable representing the number of days from collection of the index positive blood culture to administration of effective antibiotic therapy. Antibiotics administered >24 hours before collection of the index positive blood culture were excluded. In multivariable analyses, days to effective antibiotic therapy was categorized into 4 levels based on whether effective antibiotics were started concurrently with the index blood culture (from 24 hours before until 3 hours after), within 1 day (3–24 hours after the index blood culture), within 2 days (24–48 hours after the index blood culture), or after a delay of >48 hours.

**Statistical analysis**

Patient demographics and clinical characteristics were described using means and standard deviations or frequencies and proportions, as appropriate. Comparisons between patients who underwent follow-up blood culture and those who did not were performed using the Student *t* test or Wilcoxon rank-sum test for continuous variables and Pearson χ² test or Fisher exact test for categorical variables. Logistic regression was used to evaluate associations between predictors and binary outcomes, such as positivity of follow-up blood culture.

The cumulative incidence of mortality for each time-varying follow-up blood culture group was presented using Kaplan-Meier survival curves. The association between follow-up blood culture collection and time to mortality within the period of follow-up (30 days or 90 days) was modeled using Cox proportional hazards regression while adjusting for confounding variables. To explore the potential impact of follow-up blood cultures in patients with different levels of severity of illness, heterogeneity of treatment effect analyses were performed by including an interaction term between follow-up blood cultures and Pitt bacteremia scores in the Cox model.

In all time-to-event analyses, the presence of follow-up blood culture was defined as a time-varying binary variable to account for immortal time bias.14 We estimated 95% confidence intervals (CIs) for hazard ratios (HRs) using robust standard errors. Covariates included in the Cox model for risk adjustment included age, baseline health in terms of number of conditions from the Elixhauser comorbidity index, Pitt bacteremia score, presence of immunosuppression, hospital-onset of index bacteremia, and days from index positive blood culture collection to administration of effective antibiotics. Statistical analyses were performed with SAS version 9.4 software (SAS Institute, Cary, NC) and Stata/SE version 16 software (StataCorp, College Station, TX).

**Patient consent statement**

This study was determined to be exempt from requirements for patient consent by the Institutional Review Board of the University of Maryland School of Medicine. A waiver of HIPAA authorization for release of the private health information was approved.

**Results**

**Patient characteristics and follow-up blood cultures**

In total, 180 patients with a positive *P. aeruginosa* blood culture were identified, including 159 unique patients who met the inclusion criteria and 127 patients (80% of 159) with at least 1 follow-up blood culture (see Fig. 1 for patient flow diagram). Patients who had follow-up blood cultures were similar to those who did not (Table 1). All 23 patients whose bacteremia was attributed to an
indwelling vascular catheter had follow-up blood cultures obtained. Among them, 74.2% of patients received effective antibiotics within 24 hours of the index positive blood culture (median time to effective antibiotics, 4.7 hours; IQR, 0.7–25.0). In addition, >90% of patients were seen by an infectious disease consultant within 48 hours of the index positive blood culture, regardless of whether follow-up blood cultures were obtained.

The median number of follow-up blood cultures was 1 (minimum, 5). The median time to first follow-up blood culture was 52.0 hours (IQR, 32.5–100.9). Follow-up blood cultures were positive in 18 patients (14.2% of 127), including 9 cases of persistent Pseudomonal bacteremia (7.1%). Follow-up blood cultures were positive for Candida spp in 4 cases, Klebsiella pneumoniae in 3 cases, and other organisms in 4 cases. In unadjusted analyses, presence of a central line (OR, 0.78; 95% CI, 0.29–2.1; P = .20), dependence on hemodialysis (OR, 1.35; 95% CI, 0.40–4.6; P = .63), Pitt bacteremia score (OR, 0.89; 95% CI, 0.73–1.10; P = .29), and days from index positive blood culture collection to administration of effective antibiotics (OR, 1.22; 95% CI, 0.83–1.80 per 1-day increase; P = .31) were not significantly associated with isolation of a pathogen from follow-up blood culture.

Among the 94 patients with a central line present before onset of bacteremia, 74 (79%) had their line removed during the 30-day follow-up period, and 32 (34%) had their line removed before completing inpatient antibiotics. The median time to line removal was 63 hours (IQR, 23–192). Among 77 patients with follow-up blood cultures, 30 (39%) had their central lines removed before follow-up blood cultures were obtained. Of 30 patients with line removal prior to follow-up blood culture, 3 (10%) were still bacteremic at time of follow-up, compared with 7 (15%) of 47 patients whose line remained in place (P = .533, χ² test).

Reasons for obtaining follow-up blood cultures
A justification for follow-up blood cultures was documented in the charts of 58 (45.7%) of 127 eligible patients (Fig. 2). The most common justifications for follow-up blood cultures were to ensure clearance (28 cases), to guide antibiotic therapy (16 cases), “repeat until negative” (5 cases), and in response to fever (4 cases). Justification for follow-up blood culture was associated with a positive overall impression of the patient’s condition (20 cases), a negative impression in 31 cases, and no assessment of the patient’s condition in 7 cases. Follow-up blood cultures to guide antibiotic therapy (10 cases for negative impression, 3 for positive, 3 with no impression) and fever (3 for negative impression, 0 for positive, 1 with no impression) were recommended more frequently in the setting of provider concern. Follow-up blood cultures to ensure clearance or to be repeated until negative were used equally regardless of providers’ overall impression of the patient’s condition.

Mortality among patients with and without follow-up blood cultures
Unfortunately, 7 patients provided incomplete follow-up data and were censored before 30 days of follow-up (see Supplementary Appendix online for the characteristics of these patients). Also, 40 patients (25.2%) died within 30 days of their index positive blood culture, including 24 (18.9%) of 127 patients who had follow-up blood cultures and 16 (50%) of 32 patients without follow-up blood cultures. Mortality rates within the 30-day follow-up period were similar between patients whose follow-up blood cultures were negative and positive (24.1% vs 33.3%; P = .40, χ² testing).

Among those who died, median times from index positive blood culture to death in the overall sample, patients with follow-up blood culture, and patients without follow-up blood culture were 6 days (IQR, 3–12), 9.5 days (IQR, 5.5–15), and 3.5 (IQR, 2–7), respectively. Kaplan-Meier survival curves for the 30-day follow-up period are displayed in Figure 3. In unadjusted Cox regression, collection of follow-up blood cultures was not significantly associated with risk of mortality (HR, 0.59; 95% CI, 0.26–1.32; P = .20). After adjusting for age, baseline health in terms of number

---

**Fig. 1.** Flow chart depicting patient selection (excluding explanation for obtaining FUBC). *Patients were excluded if they died or were discharged within 24 hours of first positive blood culture, if they had a previous admission with a positive blood culture, or if the positive blood culture date preceded the admission date.
of conditions from the Elixhauser comorbidity index, Pitt bacteremia score, presence of immunosuppression, hospital-onset of index bacteremia, and days from index positive blood culture collection to administration of effective antibiotics, follow-up blood cultures remained nonsignificantly associated with risk of mortality (HR, 0.43; 95% CI, 0.17–1.08; P = .07) (see Supplementary Appendix online for full model).

Follow-up blood cultures for patients with low, medium, and high Pitt bacteremia scores

In risk-adjusted Cox regression, medium (HR, 4.81; 95% CI, 1.38–16.8; P = .014) and high (HR, 15.6; 95% CI, 3.77–64.4; P < .001) Pitt bacteremia scores were independently associated with increasing risk of mortality relative to a Pitt bacteremia score of 0 (see Supplementary Appendix online). The Kaplan-Meier survival curves for patients with low, medium, and high Pitt bacteremia scores are displayed in Figure 4. When comparing survival curves by log-rank test without adjustment for confounding variables, follow-up blood cultures were associated with increased survival among patients with medium Pitt bacteremia scores (P = .018) (Fig. 4).

Follow-up blood cultures were positive in 10 (21.7%) of 46 patients with Pitt bacteremia scores of zero, 6 (11.1%) of 54 patients with Pitt bacteremia scores 1–4, and 2 (7.4%) of 27 patients with Pitt bacteremia scores >4. Sources of infection for patients with low, medium, and high Pitt bacteremia scores are reported in the Supplementary Material (online). Follow-up blood cultures were positive for 2 of the 3 patients with low Pitt scores who died within 30 days of their index blood culture, 3 of 10 patients with medium Pitt scores who died within 30 days, and 1 of 11 with high Pitt scores who died within 30 days.

Sensitivity analysis using 90-day period of follow-up

Kaplan-Meier curves for an extended period of follow-up are displayed in Figure 5. These curves were not significantly different by log-rank test (P = .30). Follow-up blood cultures were not

Table 1. Description of Patients With Pseudomonas aeruginosa Bacteremia (N=159)

| Variable                                      | All Patients (n=159) | Follow-Up Blood Culture (n=127) | No Follow-Up Blood Culture (n=32) | P Value |
|-----------------------------------------------|----------------------|---------------------------------|-----------------------------------|---------|
| Age, mean y (SD)                              | 56.6 (16.3)          | 56.9 (16.5)                     | 59.3 (15.3)                       | .21     |
| Sex, male                                     | 94 (59.1)            | 76 (59.8)                       | 18 (56.3)                         | .71     |
| Race                                          |                      |                                 |                                   |         |
| Black or African American                     | 71 (44.7)            | 58 (45.7)                       | 13 (40.6)                         | .22     |
| White                                         | 77 (48.4)            | 63 (49.6)                       | 14 (43.8)                         |         |
| Hispanic                                      | 3 (1.9)              | 2 (1.6)                         | 1 (3.1)                           |         |
| ≥2 races                                      | 1 (0.6)              | 1 (0.8)                         | 0                                 |         |
| BMI (mean, SD)                                | 28.1, 7.2            | 28.3, 7.0                       | 27.1, 8.1                         | .41     |
| Elixhauser score (median, IQR)                | 5 (4–7)              | 5 (4–7)                         | 4.5 (3–7)                         | .48a    |
| Immunomodulating agents                       | 90 (56.6)            | 69 (54.3)                       | 21 (65.6)                         | .25     |
| Hemodialysis dependence                       | 31 (19.5)            | 23 (18.1)                       | 8 (25.0)                          | .38     |
| ICU care                                      | 73 (45.1)            | 60 (46.2)                       | 13 (40.6)                         | .57     |
| Foley catheter                                | 58 (36.5)            | 46 (36.2)                       | 12 (37.5)                         | .89     |
| Mechanical ventilation                        | 55 (34.8)            | 43 (34.1)                       | 12 (37.5)                         | .72     |
| Central line                                  | 94 (59.1)            | 77 (60.6)                       | 17 (53.1)                         | .44     |
| Pitt bacteremia score, median (IQR)           | 2 (1–4)              | 2 (0–4)                         | 3 (0.5–5.5)                       | .16a    |
| Hours from blood culture collection to antibiotics, median (IQR) | 4.7 (0.7–25.0) | 4.1 (0.7–24.0) | 6.4 (0.8–38.3) | .35a |
| ID consult <24 h after bacteremia             | 153 (95.6)           | 121 (95.3)                      | 31 (96.9)                         | .69     |
| Source of bacteremia                          |                      |                                 |                                   | .001    |
| Line related                                  | 23 (14.5)            | 23 (18.1)                       | 0 (0.0)                           |         |
| Urinary system infection                      | 17 (10.7)            | 13 (10.2)                       | 4 (12.5)                          |         |
| Nonurinary intra-abdominal infection          | 27 (17.0)            | 14 (11.0)                       | 13 (40.6)                         |         |
| Pneumonia                                     | 22 (13.8)            | 17 (13.4)                       | 5 (15.6)                          |         |
| Multiple sources                              | 6 (3.8)              | 6 (4.7)                         | 0 (0.0)                           |         |
| Other                                         | 24 (15.1)            | 22 (17.3)                       | 2 (6.3)                           |         |
| Unknown                                       | 40 (25.2)            | 32 (25.2)                       | 8 (25.0)                          |         |

Note. SD, standard deviation; IQR, interquartile range.

*aMann-Whitney U test.
significantly associated with risk of mortality in unadjusted Cox regression (HR, 0.70; 95% CI, 0.34–1.44; \( P = .33 \)) or adjusted Cox regression (HR, 0.56; 95% CI, 0.25–1.27; \( P = .17 \)).

**Discussion**

Unnecessary blood cultures can waste resources, complicate patient follow-up, and, when positive for a contaminant, adversely affect hospital quality metrics. In this cohort study of 5 years of clinical data from a large medical center, follow-up blood cultures for *P. aeruginosa* bacteremia were routine, but persistent bacteremia was infrequent. Follow-up blood cultures were not significantly associated with improved mortality, though exploratory analyses suggested a potential benefit when they were drawn for patients with elevated Pitt bacteremia scores.

Strategies to improve use of follow-up blood cultures may focus on the underlying infectious syndrome, the pathogen, the adequacy of treatment, or the patient’s condition. In this study, we focused on a pathogen that has been identified as an independent risk factor for breakthrough bacteremia and for which the evidence is limited. 

When persistent bacteremia was found to be infrequent, we performed exploratory analyses to identify patients who might be most likely to benefit from follow-up blood cultures, and we investigated potential differences in impact associated with severity of illness. We also explored the reasons why follow-up blood cultures were being obtained and found that they were frequently reflective, (‘repeat

![Provider Explanation for Obtaining follow-up blood culture](image_url)

Fig. 2. Provider explanation for obtaining follow-up blood culture (N = 58).

![Kaplan-Meier survival curves for patients with and without follow-up blood cultures within 30 days of follow-up. Note. BC, blood cultures. Postfubc indicates status-post follow-up blood cultures.](image_url)

Fig. 3. Kaplan-Meier survival curves for patients with and without follow-up blood cultures within 30 days of follow-up. Note. BC, blood cultures. Postfubc indicates status-post follow-up blood cultures.

![Kaplan-Meier survival curves for patients with and without follow-up blood cultures, stratified by low, medium, and high Pitt bacteremia scores. Low Pitt bacteremia score was defined by a score of 0. Medium scores were 1–4. High scores were ≥5.](image_url)

Fig. 4. Kaplan-Meier survival curves for patients with and without follow-up blood cultures, stratified by low, medium, and high Pitt bacteremia scores. Postfubc indicates status-post follow-up blood cultures. Low Pitt bacteremia score was defined by a score of 0. Medium scores were 1–4. High scores were ≥5.
Repeat blood cultures have been identified as a potentially unnecessary testing practice representing an opportunity for diagnostic stewardship. At our medical center, follow-up blood cultures are collected in 4 of 5 cases of *P. aeruginosa* bacteremia. Although others have reported similar rates of repeated cultures,4,16 we suspect that follow-up blood cultures are not necessary in all cases of *P. aeruginosa* bacteremia but have been unable to reach a local consensus on how best to de-implement this process. Thus, when consulted, infectious disease physicians continue to encourage collection of follow-up blood cultures in many cases. Despite recent adoption of protocols targeting follow-up blood cultures based on severity of illness, these protocols explicitly permit repeat cultures to ensure clearance.

Surprisingly, follow-up blood cultures were less frequently positive for patients with elevated Pitt scores. This finding may reflect an increased frequency of line-related bacteremia among the patients with low Pitt scores (see Supplementary Appendix online). However, despite a lower positivity rate, follow-up blood cultures were associated with a trend toward improved survival among patients with Pitt scores >0. Although subgroups with medium and high Pitt scores were small and clinical courses were heterogeneous, we suspect that follow-up blood cultures may support effective clinical management of patients who are severely ill with *P. aeruginosa* bacteremia. Positivity rate is often used as a proxy for clinical utility, but blood cultures may provide clinical utility when negative, particularly among the critically ill. Further investigation, including ideally a larger sample of severely ill patients with pseudomonal bacteremia, is needed before the optimal context for use of follow-up blood cultures can be identified.

Notably, follow-up blood cultures in our cohort were as frequently positive for *P. aeruginosa* as they were for unrelated but nonetheless clinically relevant pathogens. This finding may reflect the high rate of early effective antibiotic therapy or may indicate that *P. aeruginosa* bacteremia is a marker among hospitalized patients for underlying predisposition toward severe infections. Given that mortality was high (25.2%) regardless of whether persistent bacteremia was present, the poor prognosis associated with *P. aeruginosa* bacteremia may be attributable to host factors in addition to acute illness.

This study has several limitations. First, we analyzed observational data from a single medical center, and our findings therefore may not be generalizable to other clinical settings. However, in the context of other single-center studies in the literature, these results are meaningful. Second, though we adjusted for severity of illness using the Pitt bacteremia score and baseline health using the Elixhauser comorbidity index, our results are likely still susceptible to residual confounding related to severity of illness. Third, most follow-up blood cultures in our cohort were drawn within 72 hours of the index positive blood culture. Thus, our results may not be generalizable to clinical protocols that emphasize collection of follow-up blood cultures later in the course of illness or at the conclusion of therapy. Finally, the retrospective design of this study did not permit an evaluation of causal pathways. Rather, we were limited to reporting associations only.

In this retrospective observational study, follow-up blood cultures were not associated with clear or consistent benefit in either short- or long-term outcomes. Follow-up blood cultures were frequently drawn reflexively "to ensure clearance." Diagnostic stewardship initiatives can potentially reduce unnecessary culturing by targeting follow-up blood cultures based on severity of illness.

Acknowledgments. We thank the Infectious Diseases Society of America and Society for Healthcare Epidemiology of America for supporting research among medical students and early career investigators.

Financial support. A.G. was supported in the conduct of this work by the Infectious Diseases Society of America Foundation’s Grants for Emerging Researchers/Clinicians Mentorship program. J.B. received support from the Society for Healthcare Epidemiology of America Education & Research Foundation through the Epi Project Competition.

Conflicts of interest. All authors report no conflicts of interest relevant to this article.

Supplementary material. To view supplementary material for this article, please visit https://doi.org/10.1017/ash.2021.184

References

1. Kang CI, Kim SH, Park WB, *et al.* Bloodstream infections caused by antibiotic-resistant Gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. *Antimicrob Agents Chemother* 2005;49:760–766.
2. Fabre V, Sharara SL, Salinas AB, *et al.* Does this patient need blood cultures? a scoping review of indications for blood cultures in adult nonneutropenic inpatients. *Clin Infect Dis* 2020;71:1339–1347.
3. Canzoneri CN, Akhavan B, Tosar Z, *et al.* Follow-up blood cultures in Gram-negative bacteremia: are they needed? *Clin Infect Dis* 2017;65(5):1776–1779.
4. Wiggers JB, Xiong W, and Daneman N. Sending repeat cultures: is there a role in the management of bacteremic episodes? (SCRIBE study). *BMC Infect Dis* 2016;16:286.
5. Mitaka H, Gomez T, Lee YI, *et al.* Risk factors for positive follow-up blood cultures in Gram-negative bacilli bacteremia: implications for selecting who needs follow-up blood cultures. *Open Forum Infect Dis* 2020;7:oofa110.
6. Maskarinec SA, Park LP, Ruffin F, *et al.* Positive follow-up blood cultures identify high mortality risk among patients with Gram-negative bacteremias. *Clin Microbiol Infect* 2020;26:904–910.
7. Thaden JT, Park LP, Maskarinec SA, *et al.* Results from a 13-year prospective cohort study show increased mortality associated with bloodstream infections. *Open Forum Infect Dis* 2017;4:401–412.
infections caused by *Pseudomonas aeruginosa* compared to other bacteria. *Antimicrob Agents Chemother* 2017;61(6):e02671–16.

8. Fabre V, Amoah J, Cosgrove SE, *et al.* Antibiotic therapy for *Pseudomonas aeruginosa* bloodstream infections: how long is long enough? *Clin Infect Dis* 2019;69:2011–2014.

9. Rhee JY, Kwon KT, Ki HK, *et al.* Scoring systems for prediction of mortality in patients with intensive care unit-acquired sepsis: a comparison of the Pitt bacteremia score and the Acute Physiology and Chronic Health Evaluation II scoring systems. *Shock* 2009;31:146–150.

10. Al-Hasan MN, Lahr BD, Eckel-Passow JE, *et al.* Predictive scoring model of mortality in Gram-negative bloodstream infection. *Clin Microbiol Infect* 2013;19:948.

11. Epic Care Everywhere Network website. https://www.epic.com/CareEverywhere/. Accessed April 8, 2021.

12. Elixhauser A, Steiner C, Harris DR, *et al.* Comorbidity measures for use with administrative data. *Med Care* 1998;36:8–27.

13. Feldman C, Alane S, Yu V, *et al.* Severity of illness scoring systems in patients with bacteremic pneumococcal pneumonia: implications for the intensive care unit care. *Clin Microbiol Infect* 2009;15:850–857.

14. Ho AM, Dion PW, Ng CS, *et al.* Understanding immortal time bias in observational cohort studies. *Anaesthesia* 2013;68:126–130.

15. Fabre V, Klein E, Salinas AB, *et al.* A diagnostic stewardship intervention to improve blood culture use among adult non-neutropenic inpatients: the DISTRIBUTE study. *J Clin Microbiol* 2020;58:e01053.

16. Giannella M, Pascale R, Pancaldi L, *et al.* Follow-up blood cultures are associated with improved outcome of patients with Gram-negative bloodstream infections: retrospective observational cohort study. *Clin Microbiol Infect* 2020;26:897–903.

17. Lopez Dupla M, Martinez J, Vidal F, *et al.* Clinical characterization of breakthrough bacteraemia: a survey of 392 episodes. *J Intern Med* 2005;258:172–180.